Redeye raises its base case following Xspray’s announcement that XS003 has achieved bioequivalence with Tasigna, paving the way for an NDA submission in the near term. Meanwhile, the company’s lead candidate, Dasynoc, has a PDUFA date in October, offering another near-term catalyst.
LÄS MER
